| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study
|
Gui, Chloe
|
|
|
26 |
9 |
p. 1191-1203
|
artikel
|
| 2 |
Breaking the patient-reported outcome code in KRAS G12C-mutated colorectal cancer: clinical interpretation of CodeBreaK 300
|
Jensen, Lars Henrik
|
|
|
26 |
9 |
p. 1129-1130
|
artikel
|
| 3 |
Broadening our view of power in clinician–patient relationships in oncology
|
Nimmon, Laura
|
|
|
26 |
9 |
p. 1140-1142
|
artikel
|
| 4 |
Clarifying the consensus on laryngeal preservation strategies
|
Orak, Ömer
|
|
|
26 |
9 |
p. e459
|
artikel
|
| 5 |
Clarifying the consensus on laryngeal preservation strategies – Authors' reply
|
Ferrari, Marco
|
|
|
26 |
9 |
p. e460-e461
|
artikel
|
| 6 |
Concerns over future of US health advisory panel under RFK Jr
|
Gourd, Elizabeth
|
|
|
26 |
9 |
p. 1137
|
artikel
|
| 7 |
Correction to Lancet Oncol 2025; 26: 1113–22
|
|
|
|
26 |
9 |
p. e465
|
artikel
|
| 8 |
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial
|
Ma, Daniel
|
|
|
26 |
9 |
p. 1227-1239
|
artikel
|
| 9 |
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer
|
Petkar, Imran
|
|
|
26 |
9 |
p. 1127-1129
|
artikel
|
| 10 |
Establishing the China–UK Cancer Prevention and Control Alliance
|
Ma, Jun
|
|
|
26 |
9 |
p. 1132-1134
|
artikel
|
| 11 |
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
|
Zhou, Aiping
|
|
|
26 |
9 |
p. 1145-1157
|
artikel
|
| 12 |
[68Ga]Ga-FAPI-46: an imaging biomarker for FAP-positive tumours
|
Delgado Bolton, Roberto C
|
|
|
26 |
9 |
p. 1126-1127
|
artikel
|
| 13 |
[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
|
Pabst, Kim M
|
|
|
26 |
9 |
p. 1204-1214
|
artikel
|
| 14 |
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
|
Modest, Dominik Paul
|
|
|
26 |
9 |
p. 1240-1251
|
artikel
|
| 15 |
Hope against the odds
|
Adepoju, Paul
|
|
|
26 |
9 |
p. 1144
|
artikel
|
| 16 |
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer
|
Tannock, Ian F
|
|
|
26 |
9 |
p. e499-e507
|
artikel
|
| 17 |
Kenya adopts digitally enabled cancer-care model
|
Adepoju, Paul
|
|
|
26 |
9 |
p. 1139
|
artikel
|
| 18 |
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
|
Remon, Jordi
|
|
|
26 |
9 |
p. 1215-1226
|
artikel
|
| 19 |
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
|
Niazi, Tamim
|
|
|
26 |
9 |
p. 1158-1167
|
artikel
|
| 20 |
New test for breast cancer set to transform patient treatment
|
Gourd, Elizabeth
|
|
|
26 |
9 |
p. 1136
|
artikel
|
| 21 |
Oral lesion as the first sign of disseminated sarcomatoid carcinoma
|
Lombardi, Niccolò
|
|
|
26 |
9 |
p. e508
|
artikel
|
| 22 |
Pitfalls in multinational sales data analysis
|
Zhu, Xudong
|
|
|
26 |
9 |
p. e462
|
artikel
|
| 23 |
Pitfalls in multinational sales data analysis – Authors' reply
|
Jiao, Yuanshi
|
|
|
26 |
9 |
p. e463
|
artikel
|
| 24 |
Prevention and empowerment: cultural influences on prophylactic surgical decisions among BRCA mutation carriers in east Asia
|
Qi, Teng
|
|
|
26 |
9 |
p. 1142-1143
|
artikel
|
| 25 |
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
|
Tang, Ling-Long
|
|
|
26 |
9 |
p. e477-e487
|
artikel
|
| 26 |
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
|
Emmett, Louise
|
|
|
26 |
9 |
p. 1168-1177
|
artikel
|
| 27 |
Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis
|
Du, Anbang
|
|
|
26 |
9 |
p. e466-e476
|
artikel
|
| 28 |
Refining risk stratification in meningiomas: beyond TERT promoter mutations
|
Scalia, Gianluca
|
|
|
26 |
9 |
p. 1124-1126
|
artikel
|
| 29 |
Reflecting on the patient-reported outcomes from the EV-302 trial
|
Li, Jun
|
|
|
26 |
9 |
p. e464
|
artikel
|
| 30 |
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
|
Zhang, Yichen
|
|
|
26 |
9 |
p. 1252-1260
|
artikel
|
| 31 |
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
|
Tang, Ling-Long
|
|
|
26 |
9 |
p. e488-e498
|
artikel
|
| 32 |
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis
|
Groff, Karenna J
|
|
|
26 |
9 |
p. 1178-1190
|
artikel
|
| 33 |
The importance of high-quality evidence supporting cancer drug approvals
|
Vokinger, Kerstin N
|
|
|
26 |
9 |
p. 1131-1132
|
artikel
|
| 34 |
The increasing costs of NCDs and mental health conditions in South America
|
Burki, Talha
|
|
|
26 |
9 |
p. 1135
|
artikel
|
| 35 |
Truth and accountability
|
The Lancet Oncology,
|
|
|
26 |
9 |
p. 1123
|
artikel
|
| 36 |
US aid cuts affect vulnerable populations in the Democratic Republic of the Congo and Kenya
|
Devi, Sharmila
|
|
|
26 |
9 |
p. 1138
|
artikel
|
Tijdschrift beschrijving